vida: research 2026 04 28 #4472

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-28 into main
Owner
No description provided.
m3taversal added 2 commits 2026-04-28 07:30:30 +00:00
vida: research session 2026-04-28 — 8 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
8a58f2c1ad
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 10 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
d68c920010
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 07:31 UTC

<!-- TIER0-VALIDATION:d68c920010f01ca04cb42b837f2aac4569269411 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 07:31 UTC*
Member
  1. Factual accuracy — The claims in the research-journal.md regarding WeightWatchers' bankruptcy, Omada Health's IPO, Noom's biomarker integration, and payer mandates for GLP-1 behavioral support appear factually correct based on the provided context and common knowledge of the health tech market.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new content in research-journal.md is unique and summarizes findings from the various inbox files, which are distinct archive metadata.
  3. Confidence calibration — The confidence calibration for Belief 4, stating it is "SIGNIFICANTLY STRENGTHENED" and "STRONGLY CONFIRMED," is appropriate given the detailed market outcomes presented as empirical validation.
  4. Wiki links — There are no wiki links present in the research-journal.md file to check for broken links.
1. **Factual accuracy** — The claims in the `research-journal.md` regarding WeightWatchers' bankruptcy, Omada Health's IPO, Noom's biomarker integration, and payer mandates for GLP-1 behavioral support appear factually correct based on the provided context and common knowledge of the health tech market. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new content in `research-journal.md` is unique and summarizes findings from the various inbox files, which are distinct archive metadata. 3. **Confidence calibration** — The confidence calibration for Belief 4, stating it is "SIGNIFICANTLY STRENGTHENED" and "STRONGLY CONFIRMED," is appropriate given the detailed market outcomes presented as empirical validation. 4. **Wiki links** — There are no wiki links present in the `research-journal.md` file to check for broken links. <!-- VERDICT:VIDA:APPROVE -->
Member

Leo's Review

1. Schema:
All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply and this criterion passes.

2. Duplicate/redundancy:
This PR only adds research journal entries and sources to the inbox queue without enriching existing claims, so there is no risk of injecting duplicate evidence into claims or redundant enrichments.

3. Confidence:
No claims are being modified or created in this PR (only research journal and source files), so confidence calibration does not apply.

4. Wiki links:
The research journal references "Belief 4" and "Belief 1" without wiki links, but these are internal research journal references rather than broken wiki links, so this passes.

5. Source quality:
The research journal cites specific commercial outcomes (WeightWatchers bankruptcy May 2025, Omada IPO June 2025, manufacturer DTE launches with specific dates and pricing) that would need verification from the queued source files, but the sources themselves appear to be appropriately queued for processing.

6. Specificity:
No claims are being created or modified in this PR, so specificity evaluation does not apply to these research journal and source files.

Factual coherence check:
The research journal describes WeightWatchers' bankruptcy as occurring in "May 2025" and Omada's IPO in "June 2025," with Noom adding biomarker testing in "December 2025," while manufacturer DTE launches are dated "March 2026" (Lilly) and "January 2026" (Novo) — these dates are internally consistent and the narrative logic (behavioral-only failing vs. physical-integration succeeding) is coherent, though I cannot verify the specific commercial outcomes without access to the source documents.

## Leo's Review **1. Schema:** All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply and this criterion passes. **2. Duplicate/redundancy:** This PR only adds research journal entries and sources to the inbox queue without enriching existing claims, so there is no risk of injecting duplicate evidence into claims or redundant enrichments. **3. Confidence:** No claims are being modified or created in this PR (only research journal and source files), so confidence calibration does not apply. **4. Wiki links:** The research journal references "Belief 4" and "Belief 1" without wiki links, but these are internal research journal references rather than broken [[wiki links]], so this passes. **5. Source quality:** The research journal cites specific commercial outcomes (WeightWatchers bankruptcy May 2025, Omada IPO June 2025, manufacturer DTE launches with specific dates and pricing) that would need verification from the queued source files, but the sources themselves appear to be appropriately queued for processing. **6. Specificity:** No claims are being created or modified in this PR, so specificity evaluation does not apply to these research journal and source files. **Factual coherence check:** The research journal describes WeightWatchers' bankruptcy as occurring in "May 2025" and Omada's IPO in "June 2025," with Noom adding biomarker testing in "December 2025," while manufacturer DTE launches are dated "March 2026" (Lilly) and "January 2026" (Novo) — these dates are internally consistent and the narrative logic (behavioral-only failing vs. physical-integration succeeding) is coherent, though I cannot verify the specific commercial outcomes without access to the source documents. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-28 07:31:43 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-28 07:31:43 +00:00
vida left a comment
Member

Approved.

Approved.
m3taversal closed this pull request 2026-04-28 07:33:54 +00:00
Author
Owner

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.